JPS62221402A - Production of hollow fibrous separation membrane - Google Patents
Production of hollow fibrous separation membraneInfo
- Publication number
- JPS62221402A JPS62221402A JP6421986A JP6421986A JPS62221402A JP S62221402 A JPS62221402 A JP S62221402A JP 6421986 A JP6421986 A JP 6421986A JP 6421986 A JP6421986 A JP 6421986A JP S62221402 A JPS62221402 A JP S62221402A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- polysulfone
- solvent
- membrane
- separation membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 32
- 238000000926 separation method Methods 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 238000009987 spinning Methods 0.000 claims abstract description 22
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 229920002492 poly(sulfone) Polymers 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000002166 wet spinning Methods 0.000 claims abstract description 3
- 239000004695 Polyether sulfone Substances 0.000 claims abstract 5
- 229920006393 polyether sulfone Polymers 0.000 claims abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000005345 coagulation Methods 0.000 claims description 9
- 230000015271 coagulation Effects 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 239000011550 stock solution Substances 0.000 claims description 7
- 239000012510 hollow fiber Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 230000001112 coagulating effect Effects 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 23
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 238000001914 filtration Methods 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000002615 hemofiltration Methods 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 6
- 150000003457 sulfones Chemical class 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001631 haemodialysis Methods 0.000 description 5
- 230000000322 hemodialysis Effects 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 208000012998 acute renal failure Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- -1 ether sulfone Chemical class 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- 239000011475 Accrington brick Substances 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000000365 Oenanthe javanica Nutrition 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000206608 Pyropia tenera Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、血液浄化用の中空糸型人工臓器に関するもの
である。更に詳しくは、慢性あるいは急性の腎不全患者
の治療を目的とした、すぐれた濾過特性と安定性を有す
る血液透析器、血液濾過器、血圧駆動型血液濾過器等に
関するものである。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a hollow fiber type artificial organ for blood purification. More specifically, the present invention relates to hemodialyzers, hemofilters, blood pressure-driven hemofilters, etc. that have excellent filtration characteristics and stability and are intended for the treatment of patients with chronic or acute renal failure.
現在、慢性腎不全患者の治療としては、血液ゼンプを使
用した間歇的な血液透析や血液濾過が一般的に行なわれ
ている。一方、手術後の倉併症等で生じる急性腎不全患
者の治療に対しては、迅速な水分及び溶質の大量の除去
が必要となってくるため、従来の間歇的な治療法では対
応できないことが多い。Currently, intermittent hemodialysis and hemofiltration using Blood Zemp are commonly used to treat patients with chronic renal failure. On the other hand, for the treatment of patients with acute renal failure due to complications such as post-surgical complications, it is necessary to quickly remove large amounts of water and solutes, which cannot be treated with conventional intermittent treatment methods. There are many.
このような場合には連続的血液透析または血液濾過が効
果的であるが、１日〜２週間程度連続的に使用するため
、これに使用される膜には厳しい血液適合性が要求され
、また従来よシ用いられている血液透析器や血液濾過器
では、構造あるいは膜の特性から使用が不可能であった
。すなわち、従来の透析器や濾過器においては、その構
造のみならず使用される膜そのものＫついても４〜５時
間という短時間の血液浄化を目的としたものであり、従
って濾過効率を中心に膜の設計がなされているため長時
間血液と接触していると膜表面に血栓が生じ易いという
欠点があった。Continuous hemodialysis or hemofiltration is effective in such cases, but since they are used continuously for about 1 day to 2 weeks, the membrane used for this requires strict blood compatibility, and Conventionally used hemodialyzers and hemofilters cannot be used due to their structure or membrane characteristics. In other words, in conventional dialyzers and filters, not only the structure but also the membrane itself is aimed at purifying blood in a short time of 4 to 5 hours. Because of this design, there was a drawback that blood clots were likely to form on the membrane surface if it was in contact with blood for a long time.
更に、長時間の連続使用では患者の心臓に大きな負担が
かかる血液ダンプの使用は好ましくなく、患者自身の血
圧のみによって体外循環を行う治療法、すなわち血圧駆
動型血液濾過も検討されており、この場合患者の血圧に
応じた血流変動、特に血流低下によシ膜内に血栓が生じ
易いことから、従来の血液浄化器の使用は不可能であっ
た。Furthermore, it is not desirable to use a blood dump, which puts a heavy burden on the patient's heart when used continuously for a long period of time, and a treatment method that performs extracorporeal circulation using only the patient's own blood pressure, that is, blood pressure-driven hemofiltration, is also being considered. In this case, it has been impossible to use conventional blood purifiers because blood flow fluctuates depending on the patient's blood pressure, and in particular blood flow decreases, which tends to cause thrombi to form within the membrane.
本発明者らは、以上のような長時間の連続的血液透析ま
九は血液濾過、更には血液ダンプを使用しない血圧駆動
による血液濾過を安定して行うことができる中空糸型血
液浄化器を得るべく鋭意研究を進め九結果、特定の樹脂
及び樹脂原液組成を用いることによシ、すぐれた性能を
有する分離膜が得られることを見出し、更にこの知見に
基づき種々の検討を行い本発明に至っ九ものである。The present inventors have developed a hollow fiber blood purifier that can stably perform continuous hemodialysis and hemofiltration as described above, as well as blood filtration driven by blood pressure without using a blood dump. As a result of our intensive research, we discovered that a separation membrane with excellent performance could be obtained by using a specific resin and resin stock solution composition.Based on this knowledge, we conducted various studies and developed the present invention. There are nine things in total.
即ち本発明は、２重管構造の中空繊維製造用ノズルを用
い、外側の環状口から紡糸原液を、芯部から凝固液を凝
固浴中へ吐出し凝固せしめる湿式紡糸法において、紡糸
原液が、ｆ リエーテルスルホン１，６１７スルホン及
び溶剤、及び／又は金属塩、及び／又は非溶剤からなシ
、コリエーテルスルホンに対するセリスルホンの重量比
が１／９以下であることを特徴とする中空繊維状分離膜
の製造方法である。That is, the present invention provides a wet spinning method in which a hollow fiber manufacturing nozzle with a double tube structure is used, and a spinning stock solution is discharged from an outer annular port and a coagulation solution is discharged from a core into a coagulation bath and coagulated. f Liethersulfone 1,617 sulfone and a solvent, and/or a metal salt, and/or a non-solvent, and a hollow fiber separation characterized in that the weight ratio of serisulfone to coryethersulfone is 1/9 or less This is a method for manufacturing a membrane.
中空繊維状分離膜の寸法は通常、膜内径が２００〜３０
０μｍ１膜厚が１０〜１００μｍの範囲で作成が可能で
あるが、膜の強度やハウジングに挿入する際の充填率を
向上させるために膜内径は２１０〜２４０μｍ１膜厚は
３０〜５０薊の範囲が望ましい０
本発明で使用するピリエーテルスルホン及びセリスルホ
ンは、それぞれ
し単位よシなる構造を有する重合体である。The dimensions of hollow fibrous separation membranes are usually 200 to 30 mm in inner diameter.
Although it is possible to create a membrane with a thickness of 10 to 100 μm, the inner diameter of the membrane is 210 to 240 μm and the thickness is 30 to 50 μm in order to improve the strength of the membrane and the filling rate when inserting it into the housing. Desirable 0 Pyriether sulfone and seris sulfone used in the present invention are polymers each having a structure consisting of units.
コリエーテルスルホン及びコリスルホ／を溶解する極性
有機溶剤としては、例としてジメチルホルムアミド、Ｎ
−メチル−２−ピロリドンなどがあるが、コリエーテル
スルホン及びポリスルホンを溶解するものであればこれ
らに限定されない。Examples of polar organic solvents that dissolve coliethersulfone and colisulfone include dimethylformamide, N
Examples include -methyl-2-pyrrolidone, but are not limited to these as long as they can dissolve coryethersulfone and polysulfone.
また、紡糸原液または凝固液に含まれる非溶剤は、アル
コール系、ケトン系などがあるがこれらに限定されず、
また２種以上の非溶剤の組合わせも使用できる。In addition, non-solvents contained in the spinning dope or coagulation solution include, but are not limited to, alcohol-based, ketone-based, etc.
A combination of two or more types of non-solvents can also be used.
コリエーテルスルホンに対するポリスルホンの重量比は
１／９以下とするのが好ましい。１／９を越える場合は
、紡糸原液において両樹脂の相分離が生じ易くなシ、こ
の結果、安定な紡糸が困難となることが多い。仮に、紡
糸が可能な場合でも、中空繊維状分離膜の表面が例えば
凹凸状のような粗な構造となシ、このために実際の血液
を濾過する際に膜表面に血栓が生じ易く、本発明の目的
とする長時間の安定な血液濾過が不可能となる。The weight ratio of polysulfone to coliether sulfone is preferably 1/9 or less. If it exceeds 1/9, phase separation of both resins is not likely to occur in the spinning dope, and as a result, stable spinning is often difficult. Even if spinning were possible, the surface of the hollow fibrous separation membrane would have a rough structure, such as an uneven surface, which would easily cause blood clots to form on the membrane surface during actual blood filtration. Stable blood filtration over a long period of time, which is the object of the invention, becomes impossible.
一方、ｙｔｒリスルホン／＆ｌＪエーテルスルホンの重
量比が１／９以下の場合は両樹脂の相溶性は良好で、し
かもセリエーテルスルホン単独の紡糸原液組成に比べて
、ポリスルホンをわずかに添加することにより血液のｐ
過特性、すなわち濾過効率及び濾過安定性が大巾に向上
するものである。更に、紡糸原液及び凝固液に金属塩ま
たは非溶剤を適度に組合わせて用いることによって、血
液濾過効率にすぐれ、しかも極めて血栓が生じにくく、
従って長時間の安定な濾過が可能な中空繊維状分離膜を
得ることができる。On the other hand, when the weight ratio of ytr risulfone/&lJ ether sulfone is 1/9 or less, the compatibility of both resins is good, and compared to the spinning dope composition of serie ether sulfone alone, the addition of a small amount of polysulfone increases blood flow. p of
The filtration characteristics, ie, filtration efficiency and filtration stability, are greatly improved. Furthermore, by using a suitable combination of metal salts or non-solvents in the spinning dope and coagulation solution, it has excellent blood filtration efficiency and is extremely resistant to thrombus formation.
Therefore, a hollow fibrous separation membrane capable of stable filtration for a long period of time can be obtained.
紡糸原液または凝固液に含まれる金属塩は、Ｌｉｃｔ、
ＬｉＢｒ％ＮａＣ１１ＮａＢｒ、 ＫＣｌ、 ＫＢｒ
、ＭｇＣ／４、ＭｇＢｒ２、ＣａＣｌ２、ＣａＢｒ２の
少くとも１種より選ばれたものである。The metal salts contained in the spinning dope or coagulation solution are Lict,
LiBr%NaC11NaBr, KCl, KBr
, MgC/4, MgBr2, CaCl2, and CaBr2.
ノズル芯部よシ吐出し紡糸原液の内部よシ凝固せしめる
内部凝固液、及び外部より凝固せしめる凝固液の組成は
、操作性の点からは水単独であることが望ましいが、水
に金属塩及び／又はコリエーテルスルホン及びコリスル
ホンの溶剤、及び／又は非溶剤を加えることＫよシ、分
離膜の中間層の構造を変えることが可能である。ここで
用いられる金属塩、溶剤及び非溶剤は紡糸原液に用いる
ものと同様であるがこれらに限定されない。From the viewpoint of operability, it is desirable that the composition of the internal coagulating liquid that coagulates the spinning stock solution discharged from the nozzle core and the coagulating liquid that coagulates from the outside is water alone, but it is preferable that the water contains metal salts and It is possible to change the structure of the intermediate layer of the separation membrane by adding a solvent and/or a non-solvent for coliethersulfone and colisulfone. The metal salt, solvent, and nonsolvent used here are the same as those used in the spinning dope, but are not limited thereto.
以上のように、コリエーテルスルホン及びノリスルホン
を含む特定な樹脂原液組成よシ得られた中空繊維状分離
膜は、血液と接触する膜の表面状態と血液濾過速度、す
なわち除水能とのバランスが良好に保たれ、この結果血
液透析または血液濾過を極めて効率よくかつ安定に行い
得るものである。従って、慢性あるいは急性腎不全患者
の治療において、従来困難とされていた長時間の連続的
血液透析または血液濾過、更には血液ピンクを使用しな
い血圧駆動による血液濾過に対しても効果的である。As described above, the hollow fibrous separation membrane obtained with a specific resin stock solution composition containing coryether sulfone and noris sulfone has a balance between the surface condition of the membrane in contact with blood and the blood filtration rate, that is, water removal ability. is maintained well, and as a result, hemodialysis or hemofiltration can be performed extremely efficiently and stably. Therefore, in the treatment of patients with chronic or acute renal failure, it is effective for long-term continuous hemodialysis or hemofiltration, which has been considered difficult in the past, as well as blood pressure-driven hemofiltration that does not use blood pink.
実施例１
コリエーテルスルホン１４重量％、コリスルホン１重ｋ
％ 、ＮａＢｒ ５重ｔチ及びジメチルホルムアミド
８０重ｆｉ％を溶解混合した。この溶液を紡糸原液とし
て、中空繊維製造用ノズルの外側の環状口から紡糸原液
を、また芯部からは水を吐出し、水からなる凝固浴中へ
導いて凝固せしめ、４０ｍ／分の速度で巻取りを行った
。ここで紡糸温度、すなわち紡糸原液及び内部凝固液の
温度は４０℃であった。巻取った中空繊維状分離膜は６
０℃の温水中に７時間、更に流水中に１０時間の浸漬を
行った。得られた中空繊維状分離膜は内径２２０／’ｍ
１膜厚３０Ｉ！ｒｒ１であった。Example 1 Coryethersulfone 14% by weight, Corysulfone 1wk
%, 5% NaBr and 80% dimethylformamide were dissolved and mixed. Using this solution as a spinning stock solution, the spinning stock solution was discharged from the outer annular opening of the hollow fiber production nozzle, and water was discharged from the core, which was introduced into a coagulation bath consisting of water and coagulated at a speed of 40 m/min. I took up the winding. Here, the spinning temperature, that is, the temperature of the spinning dope and the internal coagulation liquid, was 40°C. The rolled hollow fibrous separation membrane is 6
It was immersed in warm water at 0° C. for 7 hours and then in running water for 10 hours. The obtained hollow fibrous separation membrane has an inner diameter of 220/'m
1 film thickness 30I! It was rr1.
この中空繊維状分離膜３０００本をピリカーボネート製
の円筒カラムに挿入し、両端をコリウレタンによシ接着
固定した後、両端部を切断し中空繊維状分離膜の開口部
を得た。中空繊維状分離膜の有効長は１０信であった。3,000 of these hollow fibrous separation membranes were inserted into a cylindrical column made of pyricarbonate, both ends of which were adhesively fixed with courethane, and then both ends were cut to obtain openings in the hollow fibrous separation membranes. The effective length of the hollow fibrous separation membrane was 10 threads.
次いで、体重約１６吟の尿管結紮した雑種犬の頚部動、
静脈に外シャントを設置し、血圧駆動による血液濾過を
行った。その際へＡＩＪンを４００ＩＵ／時間で持続注
入を行った。その結果、７００〜１５００ｍｔ／時間の
除水が安定して得られ、１００時間以上の連続濾過が可
能であシ、この量大の状態も良好であった。Next, the cervical motion of a mongrel dog weighing approximately 16 gin with ureteral ligation,
An external shunt was placed in the vein, and blood pressure-driven blood filtration was performed. At that time, AIJ was continuously infused at 400 IU/hour. As a result, water removal of 700 to 1500 mt/hour was stably obtained, continuous filtration for 100 hours or more was possible, and conditions were good even with this large amount.
以下の実施例及び比較例においては、特に断らない限り
本実施例と同様にして紡糸、評価試験等を行うものとす
る。In the following Examples and Comparative Examples, unless otherwise specified, spinning, evaluation tests, etc. will be conducted in the same manner as in this Example.
実施例２
コリエーテルスルホン１５重量％、コリスルホン１．５
重量％、ＬｉＣ４４重量％及びＮ−メチル−２−ピロリ
ドン７９．５重量％よりなる紡糸原液を用いた。巻取り
速度は５０ｍ／分であった。得られた膜は内径２３０薊
、膜厚３５μｍであった。犬による血液濾過試験では、
９００〜１４００ｆｄ／時間の除水で、１００時間以上
の安定な連続濾過が可能であった。Example 2 Coryethersulfone 15% by weight, colisulfone 1.5
A spinning dope consisting of 44% by weight of LiC and 79.5% by weight of N-methyl-2-pyrrolidone was used. The winding speed was 50 m/min. The obtained membrane had an inner diameter of 230 mm and a thickness of 35 μm. In a dog hemofiltration test,
Stable continuous filtration for 100 hours or more was possible with water removal of 900 to 1400 fd/hour.
実施例３
コリエーテルスルホン１５重量％、コリスルホン１重量
％、エタノール３重量％及びＮ−メチル−２−ピロリド
ン８１重ｉ％の組成よりなる紡糸原液を用いた。犬によ
る血液濾過試験では除水能、長時間安定性ともに良好で
あった。Example 3 A spinning dope having a composition of 15% by weight of coryethersulfone, 1% by weight of colisulfone, 3% by weight of ethanol, and 81% by weight of N-methyl-2-pyrrolidone was used. In a blood filtration test using dogs, both water removal ability and long-term stability were good.
比較例１
コリエーテルスルホン１５重量％、ＮａＢｒ３重量％及
びジメチルホルムアミド８０重量％よりなる紡糸原液を
用いた。犬による血液濾過試験では、長時間の安定性で
は良好であったが、除水能が６００ｒｎ１．７分以下と
低い値であった。この値は、腎不全患者の症状に対して
は除水能が不十分である。Comparative Example 1 A spinning dope containing 15% by weight of coryethersulfone, 3% by weight of NaBr, and 80% by weight of dimethylformamide was used. In a blood filtration test using dogs, the long-term stability was good, but the water removal ability was low at 600 rn 1.7 minutes or less. This value indicates insufficient water removal ability for the symptoms of patients with renal failure.
比較例２
ポリエーテルスルホ／１３重量％、ゴリスルホン２重量
％、ＮａＢｒ３重量％及びジメチルホルムアミド８０ｔ
ｉ％よりなる紡糸原液を用いた。血液濾過試験において
は、試験開始後約５時間は１０００〜１３００ｆｄ／時
間の高い除水能を示したが、その後急激に低下し、５０
時間抜１００ｍｆｆ１／時以下になったため実験を中止
した。使用した中空繊維状分離膜の内部に血栓が認めら
れ、これが除水量低下の原因であった。Comparative Example 2 Polyether sulfo/13% by weight, gorisulfone 2% by weight, NaBr 3% by weight and dimethylformamide 80t
A spinning dope consisting of i% was used. In the blood filtration test, a high water removal ability of 1000 to 1300 fd/hour was shown for about 5 hours after the start of the test, but after that it rapidly decreased to 50 fd/hour.
The experiment was stopped because the time cutout became less than 100mff1/hour. Thrombus was observed inside the hollow fibrous separation membrane used, and this was the cause of the decrease in water removal.
Claims (3)
の環状口から紡糸原液を、芯部から凝固液を凝固浴中へ
吐出し凝固せしめる湿式紡糸法において、紡糸原液がポ
リエーテルスルホン、ポリスルホン及び溶剤、及び／又
は金属塩、及び／又は非溶剤からなり、ポリエーテルス
ルホンに対するポリスルホンの重量比が１／９以下であ
ることを特徴とする中空繊維状分離膜の製造方法。(1) In a wet spinning method in which a hollow fiber manufacturing nozzle with a double tube structure is used, the spinning stock solution is discharged from the outer annular port and the coagulation solution is discharged from the core into a coagulation bath and coagulated. , a method for producing a hollow fibrous separation membrane comprising polysulfone and a solvent, and/or a metal salt, and/or a non-solvent, characterized in that the weight ratio of polysulfone to polyethersulfone is 1/9 or less.
該樹脂の溶剤、及び／又は該樹脂の非溶剤からなること
を特徴とする、特許請求の範囲第（１）項記載の中空繊
維状分離膜の製造方法。(2) The composition of the coagulating liquid is water, or water, a metal salt, and/or a solvent for the resin, and/or a non-solvent for the resin. A method for producing a hollow fibrous separation membrane.
ぞれ ▲数式、化学式、表等があります▼及び ▲数式、化学式、表等があります▼のくり返 し単位を有する重合体よりなることを特徴とする、特許
請求の範囲第（１）項記載の中空繊維状分離膜の製造方
法。(3) A patent claim characterized in that polyethersulfone and polysulfone are composed of polymers having repeating units of ▲ has a mathematical formula, chemical formula, table, etc. ▼ and ▲ has a mathematical formula, chemical formula, table, etc. ▼ A method for producing a hollow fibrous separation membrane according to scope (1).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6421986A JPS62221402A (en) | 1986-03-24 | 1986-03-24 | Production of hollow fibrous separation membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6421986A JPS62221402A (en) | 1986-03-24 | 1986-03-24 | Production of hollow fibrous separation membrane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62221402A true JPS62221402A (en) | 1987-09-29 |
| JPH0563214B2 JPH0563214B2 (en) | 1993-09-10 |
Family
ID=13251767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6421986A Granted JPS62221402A (en) | 1986-03-24 | 1986-03-24 | Production of hollow fibrous separation membrane |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62221402A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284137B1 (en) | 1994-06-07 | 2001-09-04 | Mitsubishi Rayon Co., Ltd. | Polysulfone porous membrane and a method of manufacturing the same |
| CN1076630C (en) * | 1997-12-17 | 2001-12-26 | 四川联合大学 | Polyether sulphone hollow fibre film and its manufacturing method and use |
-
1986
- 1986-03-24 JP JP6421986A patent/JPS62221402A/en active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284137B1 (en) | 1994-06-07 | 2001-09-04 | Mitsubishi Rayon Co., Ltd. | Polysulfone porous membrane and a method of manufacturing the same |
| CN1076630C (en) * | 1997-12-17 | 2001-12-26 | 四川联合大学 | Polyether sulphone hollow fibre film and its manufacturing method and use |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0563214B2 (en) | 1993-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4874522A (en) | Polysulfone hollow fiber membrane and process for making the same | |
| JPH0647262A (en) | Method for highly efficient removal of low-density lipoprotein from whole blood | |
| WO1997034687A1 (en) | Hollow yarn membrane used for blood purification and blood purifier | |
| US5736046A (en) | High-flux hollow-fiber membrane with enhanced transport capability and process for making same | |
| WO2000072950A1 (en) | Cellulose derivative hollow fiber membrane | |
| JP3934340B2 (en) | Blood purifier | |
| JPS62221402A (en) | Production of hollow fibrous separation membrane | |
| JP2703266B2 (en) | Polysulfone hollow fiber membrane and method for producing the same | |
| JPH053335B2 (en) | ||
| JP4103037B2 (en) | Diaphragm cleaning hollow fiber membrane and method for producing the same | |
| JP2007105262A (en) | Continuous hemofiltration apparatus | |
| WO2016182015A1 (en) | Porous hollow fiber membrane and manufacturing method therefor | |
| JP3424810B2 (en) | High performance blood purification membrane | |
| JPS62121608A (en) | Method for producing hollow yarn membrane for purifying blood | |
| JPH0211263B2 (en) | ||
| JPS61113458A (en) | Blood purifier | |
| JP2000210544A (en) | Production of semipermeable membrane | |
| JP4164730B2 (en) | Selective separation membrane | |
| KR930003740B1 (en) | Producing method of polysulfon membrane | |
| JP3241855B2 (en) | Porous membrane filled with inorganic salts | |
| JP7261328B2 (en) | Tubular Separation Membrane and Tubular Separation Membrane Module | |
| JPS61113460A (en) | Hollow yarn membrane for purifying blood | |
| JPS61293502A (en) | Separation film for purifying blood | |
| JPH09308684A (en) | Selective separating membrane | |
| JPH07148252A (en) | Hollow fiber membrane for blood puriification |